Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Journal Article (Journal Article)

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and high-dose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted re-assessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections.

Full Text

Duke Authors

Cited Authors

  • Coit, DG; Thompson, JA; Algazi, A; Andtbacka, R; Bichakjian, CK; Carson, WE; Daniels, GA; DiMaio, D; Ernstoff, M; Fields, RC; Fleming, MD; Gonzalez, R; Guild, V; Halpern, AC; Hodi, FS; Joseph, RW; Lange, JR; Martini, MC; Materin, MA; Olszanski, AJ; Ross, MI; Salama, AK; Skitzki, J; Sosman, J; Swetter, SM; Tanabe, KK; Torres-Roca, JF; Trisal, V; Urist, MM; McMillian, N; Engh, A

Published Date

  • April 2016

Published In

Volume / Issue

  • 14 / 4

Start / End Page

  • 450 - 473

PubMed ID

  • 27059193

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2016.0051


  • eng

Conference Location

  • United States